Company Focus
Roche
Latest Roche News
Biotechnology
Privately-held Flare Therapeutics, a US biotech targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, has entered into a strategic discovery collaboration with Swiss pharma giant Roche. 14 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company developing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders.
Latest News & Features of interest to Roche
Pharmaceutical
Santhera Pharmaceuticals has signed an exclusive distribution agreement with GENESIS Pharma for Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in 20 markets in Central and Eastern Europe. 10 September 2024
Pharmaceutical
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Biotechnology
Epsilogen, a specialist in the development of immunoglobulin E (IgE) antibodies to treat cancer, has announced the completion of a £12.5 million ($16.4 million) Series B expansion financing. 9 September 2024
Biotechnology
MBX Biosciences, a US biopharma focused on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders, has announced the launch of its initial public offering (IPO). 9 September 2024
Biotechnology
Chinese companies Innovent Biologics and GenFleet have recently secured approval from China’s National Medical Products Administration (NMPA) for Dupert (fulzerasib). 9 September 2024
Biotechnology
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Biotechnology
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
Biotechnology
ZipBio, a newly launched start-up based in Seattle, USA, is aiming to set a new standard in the development of biologics and gene therapies by utilizing generative AI technology. 9 September 2024
Biotechnology
Johnson & Johnson has released updated data from its Phase III MARIPOSA study, testing a combination of Rybrevant (amivantamab-vmjw) and lazertinib. 9 September 2024
Pharmaceutical
Israeli-headquartered RedHill Biopharma has announced the placement of its low-dose rifabutin-triple therapy, Talicia, as an empirically-prescribed fist-line choice for Helicobacter pylori (H. pylori) infection in new American College of Gastroenterology (ACG) guidelines 9 September 2024
Latest In Brief for Roche
Latest Related Ones To Watch News
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
14 November 2024
13 November 2024
12 November 2024
8 November 2024
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze